Sally R. Ellingson

Sally R. Ellingson

Auto-generated profile, based on publicly available information

Sally R. Ellingson

Markey Cancer Center University of Kentucky Lexington Kentucky USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2023 in F1000Research
Verified
Journal Article
Open access
PDF file
CRCaellin M. Rodgers
Caellin M. Rodgers
SESally R. Ellingson
Sally R. Ellingson
PCParag Chatterjee
Parag Chatterjee
Artificial Intelligence (AI) and machine learning are the current forefront of computer science and technology. AI and related sub-disciplines, including machine learning, are essential technologies which have enabled the widespread use of smart technology, such as smart phones, smart home appliances and even electric toothbrushes. It is AI that allows the devices used day-to-day across people’s personal lives, working lives and in industry to better anticipate and respond to our needs. However, the use of AI technology comes with a range of ethical questions – including issues around privacy, security, reliability, copyright/plagiarism and whether AI is capable of independent, conscious thought. We have seen several issues related to racial and sexual bias in AI in the recent times, putting the reliability of AI in question. Many of these issues have been brought to the forefront of cultural awareness in late 2022, early 2023, with the rise of AI art programs (and the copyright issues arising from the deep-learning methods employed to train this AI), and the popularity of ChatGPT alongside its ability to be used to mimic human output, particularly in regard to academic work. In critical areas like healthcare, the errors of AI can be fatal. With the incorporation of AI in almost every sector of our everyday life, we need to keep asking ourselves— can we trust AI, and how much? This Editorial outlines the importance of openness and transparency in the development and applications of AI to allow all users to fully understand both the benefits and risks of this ubiquitous technology, and outlines how the Artificial Intelligence and Machine Learning Gateway on F1000Research meets these needs.

14 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KHKristen Hill
Kristen Hill
AJAnthony McDowell, Jr.
Anthony McDowell, Jr.
RMRob McCorkle
Rob McCorkle
ESErin Schuler
Erin Schuler
SESally R. Ellingson
Sally R. Ellingson
Jill KolesarJill Kolesar
Jill Kolesar
Artesunate is the most common treatment for malaria throughout the world. Artesunate has anticancer activity likely through the induction of reactive oxygen species, the same mechanism of action utilized in Plasmodium falciparum infections. Components of the kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway, which regulates cellular response to oxidative stress, are mutated in approximately 30% of non-small-cell lung cancers (NSCLC); therefore, we tested the hypothesis that KEAP1 is required for artesunate sensitivity in NSCLC. Dose response assays identified A549 cells, which have a G333C-inactivating mutation in KEAP1, as resistant to artesunate, with an IC50 of 23.6 µM, while H1299 and H1563 cells were sensitive to artesunate, with a 10-fold lower IC50. Knockdown of KEAP1 through siRNA caused increased resistance to artesunate in H1299 cells. Alternatively, the pharmacological inhibition of NRF2, which is activated downstream of KEAP1 loss, by ML385 partially restored sensitivity of A549 cells to artesunate, and the combination of artesunate and ML385 was synergistic in both A549 and H1299 cells. These findings demonstrate that KEAP1 is required for the anticancer activity of artesunate and support the further development of NRF2 inhibitors to target patients with mutations in the KEAP1/NRF2 pathway.

Verified
Journal Article
Open access
PDF file
LCLUKSANA CHAISWING
LUKSANA CHAISWING
FXFangfang Xu
Fangfang Xu
YZYanming Zhao
Yanming Zhao
JTJon Thorson
Jon Thorson
CWChi Wang
Chi Wang
DCDaret K. St. Clair
Daret K. St. Clair
Aberrant levels of reactive oxygen species (ROS) are potential mechanisms that contribute to both cancer therapy efficacy and the side effects of cancer treatment. Upregulation of the non-canonical redox-sensitive NF-kB family member, RelB, confers radioresistance in prostate cancer (PCa). We screened FDA-approved compounds and identified betamethasone (BET) as a drug that increases hydrogen peroxide levels in vitro and protects non-PCa tissues/cells while also enhancing radiation killing of PCa tissues/cells, both in vitro and in vivo. Significantly, BET increases ROS levels and exerts different effects on RelB expression in normal cells and PCa cells. BET induces protein expression of RelB and RelB target genes, including the primary antioxidant enzyme, manganese superoxide dismutase (MnSOD), in normal cells, while it suppresses protein expression of RelB and MnSOD in LNCaP cells and PC3 cells. RNA sequencing analysis identifies B-cell linker protein (BLNK) as a novel RelB complementary partner that BET differentially regulates in normal cells and PCa cells. RelB and BLNK are upregulated and correlate with the aggressiveness of PCa in human samples. The RelB-BLNK axis translocates to the nuclear compartment to activate MnSOD protein expression. BET promotes the RelB-BLNK axis in normal cells but suppresses the RelB-BLNK axis in PCa cells. Targeted disruptions of RelB-BLNK expressions mitigate the radioprotective effect of BET on normal cells and the radiosensitizing effect of BET on PCa cells. Our study identified a novel RelB complementary partner and reveals a complex redox-mediated mechanism showing that the RelB-BLNK axis, at least in part, triggers differential responses to the redox-active agent BET by stimulating adaptive responses in normal cells but pushing PCa cells into oxidative stress overload.

4 November 2024 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
IIIbrahim A. Imam
Ibrahim A. Imam
SAShatha Al Adawi
Shatha Al Adawi
XLXiaoqi Liu
Xiaoqi Liu
SESally Ellingson
Sally Ellingson
CBChristine F. Brainson
Christine F. Brainson
QSQing Shao
Qing Shao

15 June 2020
Verified
Book Chapter
Closed access
PDF file
BDBrian Davis
Brian Davis
KMKevin Mcloughlin
Kevin Mcloughlin
JAJonathan Allen
Jonathan Allen
SESally R. Ellingson
Sally R. Ellingson